PRPH - ProPhase Labs Inc Stock Price, Fair Value and News

5.03USD-0.08 (-1.57%)Market Closed

Market Summary

USD5.03-0.08

Market Closed

-1.57%

PRPH Stock Price

View Fullscreen

PRPH RSI Chart

PRPH Valuation

Market Cap

96.0M

Price/Earnings (Trailing)

-4.07

Price/Sales (Trailing)

3.34

EV/EBITDA

-4.08

Price/Free Cashflow

-5.66

PRPH Price/Sales (Trailing)

PRPH Profitability

EBT Margin

-112.12%

Return on Equity

-52.59%

Return on Assets

-26.21%

Free Cashflow Yield

-17.66%

PRPH Fundamentals

PRPH Revenue

Revenue (TTM)

28.7M

Rev. Growth (Yr)

-81.17%

Rev. Growth (Qtr)

3.86%

PRPH Earnings

Earnings (TTM)

-23.6M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

28.41%

Breaking Down PRPH Revenue

Last 7 days

-0.4%

Last 30 days

-19.8%

Last 90 days

Trailing 12 Months

-40.7%

How does PRPH drawdown profile look like?

PRPH Financial Health

Current Ratio

1.88

Debt/Equity

0.07

Debt/Cashflow

-5.79

PRPH Investor Care

Shares Dilution (1Y)

11.03%

Diluted EPS (TTM)

-1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	28.7M	0	0	0
2023	94.4M	78.5M	62.7M	44.4M
2022	87.8M	105.2M	113.9M	122.6M
2021	27.9M	33.4M	39.0M	79.0M
2020	9.4M	11.4M	12.5M	14.5M
2019	12.0M	10.5M	10.8M	9.9M
2018	12.5M	13.8M	13.2M	13.1M
2017	4.0M	4.8M	6.5M	9.9M
2016	15.8M	14.6M	11.6M	4.2M
2015	21.8M	22.2M	21.4M	20.6M
2014	23.7M	23.5M	22.7M	22.1M
2013	23.9M	24.0M	24.5M	25.0M
2012	20.3M	20.5M	20.8M	22.4M
2011	15.7M	16.3M	16.2M	17.5M
2010	0	18.0M	16.3M	14.5M
2009	0	0	0	19.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ProPhase Labs Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2023	karkus ted william	gifted	-	-	-50,000	ceo & chairman
Apr 05, 2023	karkus ted william	gifted	-	-	50,000	ceo & chairman
Apr 03, 2023	karkus ted william	gifted	-	-	-100,000	ceo & chairman
Feb 01, 2023	karkus ted william	sold (taxes)	-2,195,000	8.18	-268,337	ceo & chairman
Feb 01, 2023	karkus ted william	acquired	300,000	0.6	500,000	ceo & chairman
Jan 13, 2023	karkus ted william	sold (taxes)	-2,988,000	9.36	-319,231	ceo & chairman
Jan 13, 2023	karkus ted william	acquired	360,000	0.6	600,000	ceo & chairman
Oct 16, 2022	karkus ted william	sold (taxes)	-3,303,000	10.41	-317,291	ceo & chairman
Oct 16, 2022	karkus ted william	acquired	360,000	0.6	600,000	ceo & chairman
Aug 10, 2022	karkus ted william	sold (taxes)	-3,432,000	10.84	-316,605	ceo & chairman

Which funds bought or sold PRPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	78,318	259,855	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	43,821	43,821	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	reduced	-36.57	-15,591	153,895	-%
May 15, 2024	Royal Bank of Canada	reduced	-95.87	-1,000	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	0.77	45,214	147,393	-%
May 15, 2024	PERRITT CAPITAL MANAGEMENT INC	reduced	-0.23	166,211	554,479	0.30%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-29.59	530	68,375	-%
May 15, 2024	SVB WEALTH LLC	unchanged	-	92,947	308,393	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	71,602	237,572	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	33,000	112,000	-%

Are Funds Buying or Selling PRPH?

Are funds buying PRPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRPH

No. of Funds

Unveiling ProPhase Labs Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	karkus ted william	20.3%	3,683,750	SC 13D/A
Apr 05, 2023	karkus ted william	20.9%	3,583,750	SC 13D/A
Apr 04, 2023	karkus ted william	20.9%	3,583,750	SC 13D/A
Feb 02, 2023	karkus ted william	21.6%	3,683,750	SC 13D/A
Jan 17, 2023	karkus ted william	22.8%	3,952,087	SC 13D/A
Oct 18, 2022	karkus ted william	24.9%	4,271,318	SC 13D/A
May 26, 2022	karkus ted william	27.3%	4,905,214	SC 13D/A
May 10, 2021	karkus ted william	28.8%	5,149,528	SC 13D/A
Aug 17, 2020	karkus ted william	34.7%	4,843,944	SC 13D/A
Mar 30, 2020	karkus ted william	33.6%	4,574,504	SC 13D/A

Recent SEC filings of ProPhase Labs Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	DEF 14A	DEF 14A
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	8-K/A	Current Report
May 09, 2024	8-K/A	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 18, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report
Mar 21, 2024	4/A	Insider Trading
Mar 19, 2024	3	Insider Trading

Peers (Alternatives to ProPhase Labs Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

ProPhase Labs Inc News

Latest updates

ProPhase Labs Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	3.9%	3,634	3,499	8,365	13,217	19,303	21,824	24,200	29,092	47,531	46,344	45,157	9,472	9,142	15,271	5,163	3,840	3,623	1,888	3,141	2,766	1,651
Gross Profit	85.8%	-433	-3,056	2,327	6,448	10,520	11,284	11,973	18,720	28,677	-	24,618	3,977	4,466	8,927	1,870	1,042	1,279	415	1,000	834	261
Operating Expenses	-5.2%	7,865	8,296	8,805	11,106	9,645	16,374	10,020	8,133	12,531	-	10,941	7,624	5,916	7,706	4,523	1,609	1,220	1,227	1,466	1,295	1,529
S&GA Expenses	-100.0%	-	8,022	8,245	9,937	8,298	12,743	7,512	6,306	7,824	-	7,780	5,938	4,993	3,782	3,623	1,552	1,155	1,168	132	302	342
R&D Expenses	-0.7%	272	274	428	572	144	479	110	28.00	35.00	-	104	208	93.00	115	452	57.00	65.00	59.00	86.00	57.00	95.00
EBITDA Margin	-141.5%	-0.83*	-0.34*	-0.16*	-0.03*	0.14*	0.23*	0.38*	0.36*	0.26*	0.11*	0.12*	0.03*	0.00*	-	-	-	-	-	-	-	-
Interest Expenses	30.0%	642	494	275	291	215	129	201	201	233	-	278	296	323	251	254	41.00	-	-	-	-	-
Income Taxes	11.9%	-2,566	-2,914	-1,644	-1,474	14.00	-2,745	809	2,965	3,416	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	24.3%	-8,831	-11,665	-6,785	-4,914	564	-5,189	1,777	10,411	15,910	-	9,621	-3,978	-1,395	1,057	-	-	-	-	-	-	-
EBT Margin	-118.3%	-1.12*	-0.51*	-0.26*	-0.10*	0.08*	0.19*	0.33*	0.30*	0.21*	0.06*	0.07*	-0.06*	-0.07*	-	-	-	-	-	-	-	-
Net Income	28.4%	-6,265	-8,751	-5,141	-3,440	550	-2,444	968	7,446	12,494	-	10,589	-3,978	-1,395	1,057	-978	-408	70.00	-809	-467	-428	-1,238
Net Income Margin	-117.3%	-0.82*	-0.38*	-0.17*	-0.06*	0.07*	0.15*	0.28*	0.25*	0.18*	0.07*	0.08*	-0.14*	-0.05*	-	-	-	-	-	-	-	-
Free Cashflow	-2303.3%	-5,119	-213	-4,679	-6,982	451	786	2,607	4,796	20,262	-4,672	-4,672	-5,547	4,417	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	90.00	92.00	92.00	91.00	95.00	88.00	98.00	98.00	100	89.00	73.00	76.00	85.00	31.00	23.00	12.00	12.00	12.00	16.00	16.00	17.00
Current Assets	-5.3%	45.00	48.00	50.00	55.00	61.00	61.00	70.00	70.00	73.00	61.00	44.00	58.00	67.00	16.00	18.00	10.00	10.00	10.00	13.00	13.00	14.00
Cash Equivalents	7.9%	2.00	2.00	1.00	4.00	10.00	9.00	23.00	24.00	26.00	9.00	9.00	18.00	33.00	7.00	11.00	3.00	1.00	0.00	1.00	1.00	2.00
Inventory	-2.2%	4.00	4.00	5.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	9.00	15.00	16.00	3.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00
Net PPE	-	-	-	13.00	9.00	9.00	7.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	4.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Goodwill	0%	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	1.00	1.00	1.00	1.00	-	-	-	-	-	-	-
Liabilities	6.2%	45.00	43.00	35.00	32.00	35.00	24.00	30.00	30.00	33.00	31.00	24.00	29.00	33.00	21.00	12.00	1.00	1.00	1.00	1.00	1.00	-
Current Liabilities	14.6%	24.00	21.00	16.00	14.00	18.00	16.00	17.00	17.00	20.00	16.00	10.00	14.00	18.00	6.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Long Term Debt	-100.0%	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-9.1%	45.00	49.00	56.00	59.00	60.00	64.00	68.00	68.00	66.00	59.00	48.00	48.00	53.00	11.00	11.00	11.00	11.00	11.00	14.00	15.00	16.00
Retained Earnings	-124.6%	-11.29	-5.03	4.00	9.00	12.00	12.00	14.00	13.00	10.00	3.00	-7.95	-3.97	-2.57	-3.63	-2.65	-2.24	-2.31	-1.51	2.00	2.00	4.00
Additional Paid-In Capital	1.3%	120	119	118	114	111	109	108	106	106	105	104	99.00	103	62.00	61.00	61.00	60.00	60.00	60.00	60.00	60.00
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.00	5.00	6.00	6.00	6.00	6.00	6.00	6.00
Shares Outstanding	0%	18.00	18.00	18.00	17.00	17.00	16.00	16.00	16.00	15.00	15.00	16.00	-	15.00	12.00	-	-	-	-	-	-	-
Float	-	-	-	-	100	-	-	-	152	-	-	-	73.00	-	-	-	13.00	-	-	-	19.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-2303.3%	-5,119	-213	-4,654	-6,957	476	811	2,632	4,821	20,287	-4,647	-5,522	4,442	-7,892	-6,768	-481	4,372	285	-428	-889	-927	1,403
Share Based Compensation	135.1%	1,589	676	857	1,056	947	1,007	1,969	528	482	745	934	1,076	428	780	283	198	198	188	180	180	196
Cashflow From Investing	292.6%	2,435	-1,264	332	1,215	-1,652	-5,003	-670	-488	4,084	5,484	-3,372	-14,946	-6,832	2,658	-1,120	-2,532	-22.00	2,787	808	-474	2,422
Cashflow From Financing	-22.3%	2,271	2,924	1,200	-47.00	1,680	-9,498	-3,122	-6,181	-7,222	-962	-	-4,546	40,635	66.00	-	-	-	-2,893	-	-	-2,929
Dividend Payments	-	-	-	-	-	-	2.00	-	4,705	4,646	-	-	-	-	-	-	-	-	2,893	-	-	2,929
Buy Backs	-	-	-	-	47.00	541	952	50.00	-	1,150	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PRPH Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues, net	$ 3,634	$ 19,303
Cost of revenues	4,067	8,783
Gross (loss) profit	(433)	10,520
Operating expenses:
Diagnostic expenses	0	1,203
General and administration	7,593	8,298
Research and development	272	144
Total operating expenses	7,865	9,645
(Loss) Income from operations	(8,298)	875
Interest income, net	0	11
Interest expense	(515)	(215)
Other expense	(18)	(107)
(Loss) Income from operations before income taxes	(8,831)	564
Income tax benefit (expense)	2,566	(14)
(Loss) income from operations after income taxes	(6,265)	550
Net (loss) income	(6,265)	550
Other comprehensive income (loss):
Unrealized gain (loss) on marketable debt securities	160	(665)
Total comprehensive loss	$ (6,105)	$ (115)
Earnings (loss) per share:
Earnings per share, basic (in dollars per share)	$ (0.35)	$ 0.03
Earnings per share, diluted (in dollars per share)	$ (0.35)	$ 0.03
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic (in shares)	18,045	16,748
Weighted average common shares outstanding, diluted (in shares)	18,045	18,061

PRPH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 1,175	$ 1,609
Restricted cash	561	540
Marketable debt securities, available for sale	58	3,127
Accounts receivable, net	35,116	36,313
Inventory, net	3,758	3,841
Prepaid expenses and other current assets	4,377	2,155
Total current assets	45,045	47,585
Property, plant and equipment, net	12,797	12,898
Prepaid expenses, net of current portion	732	832
Operating lease right-of-use asset, net	4,462	4,572
Intangible assets, net	11,687	12,333
Goodwill	5,231	5,231
Deferred tax asset	9,762	7,313
Other assets	316	1,163
TOTAL ASSETS	90,032	91,927
Current liabilities
Accounts payable	11,759	9,383
Accrued diagnostic services	268	314
Accrued advertising and other allowances	8	24
Finance lease liabilities	1,840	1,840
Operating lease liabilities	959	953
Short-term loan payable, net of discount of $396	2,381	0
Deferred revenue	1,630	2,382
Income tax payable	3,005	3,278
Other current liabilities	2,057	2,683
Total current liabilities	23,907	20,857
Non-current liabilities:
Secured long-term debt, net of discount of $334 and $340	2,926	2,924
Unsecured promissory notes, net of discount of $232 and $266	7,368	7,334
Due to sellers (see Note 3)	2,000	2,000
Deferred revenue, net of current portion	1,100	1,100
Operating lease liabilities, net of current portion	4,122	4,237
Finance lease liabilities, net of current portion	3,742	4,092
Total non-current liabilities	21,258	21,687
Total liabilities	45,165	42,544
COMMITMENTS AND CONTINGENCIES
Stockholders’ equity
Preferred stock authorized 1,000,000, $0.0005 par value, no shares issued and outstanding	0	0
Common stock authorized 50,000,000, $0.0005 par value, 18,045,029 and 18,045,029 shares outstanding, respectively	18	18
Additional paid-in capital	120,283	118,694
Accumulated deficit	(11,294)	(5,029)
Treasury stock, at cost, 18,940,967 and 18,940,967 shares, respectively	(64,000)	(64,000)
Accumulated other comprehensive loss	(140)	(300)
Total stockholders’ equity	44,867	49,383
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 90,032	$ 91,927

About ProPhase Labs Inc

ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

CEO	Mr. Ted William Karkus
WEBSITE	prophaselabs.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	129

ProPhase Labs Inc Frequently Asked Questions

What is the ticker symbol for ProPhase Labs Inc? What does PRPH stand for in stocks?

PRPH is the stock ticker symbol of ProPhase Labs Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ProPhase Labs Inc (PRPH)?

As of Fri May 17 2024, market cap of ProPhase Labs Inc is 95.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRPH stock?

You can check PRPH's fair value in chart for subscribers.

What is the fair value of PRPH stock?

You can check PRPH's fair value in chart for subscribers. The fair value of ProPhase Labs Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ProPhase Labs Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ProPhase Labs Inc a good stock to buy?

The fair value guage provides a quick view whether PRPH is over valued or under valued. Whether ProPhase Labs Inc is cheap or expensive depends on the assumptions which impact ProPhase Labs Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRPH.

What is ProPhase Labs Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PRPH's PE ratio (Price to Earnings) is -4.07 and Price to Sales (PS) ratio is 3.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRPH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ProPhase Labs Inc's stock?

In the past 10 years, ProPhase Labs Inc has provided 0.174 (multiply by 100 for percentage) rate of return.